Rapid Micro Biosystems (NASDAQ:RPID) Rating Lowered to Sell at Wall Street Zen

Rapid Micro Biosystems (NASDAQ:RPID) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.

Rapid Micro Biosystems Stock Down 17.3%

RPID stock opened at $2.83 on Friday. The stock has a market capitalization of $125.43 million, a PE ratio of -2.64 and a beta of 1.38. The company has a fifty day moving average of $3.97 and a 200-day moving average of $3.55. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.36 and a current ratio of 3.31. Rapid Micro Biosystems has a one year low of $1.86 and a one year high of $4.94.

Rapid Micro Biosystems (NASDAQ:RPID) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). The firm had revenue of $11.28 million for the quarter, compared to analyst estimates of $10.93 million. Rapid Micro Biosystems had a negative return on equity of 95.40% and a negative net margin of 140.30%. As a group, analysts expect that Rapid Micro Biosystems will post -1.1 EPS for the current year.

Insider Activity at Rapid Micro Biosystems

In other news, CFO Sean M. Wirtjes sold 7,480 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $4.32, for a total transaction of $32,313.60. Following the transaction, the chief financial officer directly owned 556,194 shares of the company’s stock, valued at $2,402,758.08. This represents a 1.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert G. Jr. Spignesi sold 17,922 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $4.11, for a total transaction of $73,659.42. Following the transaction, the chief executive officer directly owned 1,169,848 shares in the company, valued at approximately $4,808,075.28. This trade represents a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 249,705 shares of company stock valued at $1,021,364 over the last 90 days. Company insiders own 29.96% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RPID. Millennium Management LLC purchased a new position in Rapid Micro Biosystems in the fourth quarter valued at about $338,000. 683 Capital Management LLC purchased a new stake in shares of Rapid Micro Biosystems during the 4th quarter worth approximately $350,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Rapid Micro Biosystems during the 4th quarter worth approximately $71,000. Fifth Lane Capital LP acquired a new stake in shares of Rapid Micro Biosystems in the 4th quarter worth approximately $51,000. Finally, Barclays PLC acquired a new stake in shares of Rapid Micro Biosystems in the 4th quarter worth approximately $72,000. 52.60% of the stock is currently owned by institutional investors and hedge funds.

More Rapid Micro Biosystems News

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: Record revenue and raised 2026 outlook — RPID reported Q4 revenue of $11.3M and full‑year 2025 revenue of $33.6M (both record levels) and set 2026 revenue guidance of $37.0M–$41.0M with 30–38 expected system placements, signaling ongoing commercial traction. GlobeNewswire: Record Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Large customer follow‑on orders — The company announced multi‑system orders from Samsung Biologics and expanded deployments with Amgen, validating Growth Direct adoption among big pharma/CDMOs and supporting recurring system + consumables revenue upside. GlobeNewswire: Samsung Biologics Order
• Positive Sentiment: Analyst commentary supports secular growth thesis — Independent write‑ups highlight big‑pharma adoption as a key growth driver that could expand recurring revenue (service/consumables) over time. Seeking Alpha: Big‑Pharma Adoption Driving Growth
• Neutral Sentiment: Guidance near consensus but execution risk remains — 2026 revenue midpoint is close to street expectations (~$39M) and gross margin guidance (~20%) is modest; outcomes depend on hitting system placement targets and margin improvement. Yahoo Finance: Q4 2025 Earnings Preview
• Neutral Sentiment: Earnings‑call tone mixed — Management emphasized commercial progress but flagged margin and scaling pressures, producing a balanced (not unequivocally bullish) message. TipRanks: Earnings Call Summary
• Negative Sentiment: EPS miss and continued unprofitability — Q4 EPS of ($0.28) missed consensus ($0.23), and the company remains loss‑making with negative margins and ROE, a key near‑term concern for shareholders. MarketBeat: Q4 Earnings
• Negative Sentiment: Insider selling by multiple senior executives — Recent Form 4 filings show CEO, CFO and COO sales (CFO sold 7,480 shares at ~$4.32; CEO and COO also sold), which can amplify selling pressure or raise questions about insider conviction. InsiderTrades: Insider Selling

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.